Skip to main navigation Skip to search Skip to main content

Novel arylsulfoanilide-oxindole hybrid as an anticancer agent that inhibits translation initiation

  • Amarnath Natarajan
  • , Yuhong Guo
  • , Frederick Harbinski
  • , Yun Hua Fan
  • , Han Chen
  • , Lia Luus
  • , Jana Diercks
  • , Huseyin Aktas
  • , Michael Chorev
  • , Jose A. Halperin*
  • *Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

194 Scopus citations

Abstract

Structure-activity relationship studies of substituted arylsulfoanilides as antiproliferatives, which are mediated by the partial depletion of intracellular Ca2+ stores, resulted in the identification of compounds with micromolar activity against lung cancer cells in a growth inhibition assay. Incorporating the substitution pattern of the best arylsulfoanilides onto the 3-phenyloxindole scaffold resulted in a potent arylsulfoanilide-oxindole hybrid, 27. Compound 27 inhibits cancer cell growth by partial depletion of intracellular Ca2+ stores and phosphorylation of eIF2α.

Original languageEnglish
Pages (from-to)4979-4982
Number of pages4
JournalJournal of Medicinal Chemistry
Volume47
Issue number21
DOIs
StatePublished - 7 Oct 2004
Externally publishedYes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Fingerprint

Dive into the research topics of 'Novel arylsulfoanilide-oxindole hybrid as an anticancer agent that inhibits translation initiation'. Together they form a unique fingerprint.

Cite this